Investigation of the usefulness of insulin degludec in patients with type 1 diabetes

Investigation of the usefulness of insulin degludec in patients with type 1 diabetes - Investigation of the usefulness of insulin degludec in patients with type 1 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010893

Enrollment

Registered

2013-06-07

Start date

2013-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetes

Interventions

In patients who are injecting long-acting insulin once or twice daily switched to insulin degludec once daily injection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)type 1 diabetes with Basal-Bolus therapy using insulin glargine or insulin detemir(more than 6 month) 2)HbA1c:=<9% 3)subjcets whose age are more than 20 years and under 80 years.

Exclusion criteria

Exclusion criteria: 1)type2 diabetes 2)patients with starvation state or unstable appetite. 3)patients with serious liver,renal dysfunction 4)judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Change of HbA1c level	—

Secondary

Measure	Time frame
Changes of fasting plasma glucose (FPG), frequency of hypoglycemic events and glycated albumin	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026